Memphasys Limited (FRA:IG7)

Germany · Delayed Price · Currency is EUR

0.0015

0.00 (0.00%)

Last updated: Oct 12, 2026, 8:36 AM CET

Market Cap	9.62M +89.4%
Revenue (ttm)	398.42K +24.9%
Net Income	-2.48M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,000
Open	0.0015
Previous Close	0.0015
Day's Range	0.0015 - 0.0015
52-Week Range	0.0010 - 0.0050
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2006

Employees 24

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol IG7

Financial Performance

In fiscal year 2026, Memphasys's revenue was 657,968, an increase of 24.87% compared to the previous year's 526,921. Losses were -4.10 million, -18.57% less than in 2025.

Financial numbers in AUD Financial Statements